Butal/Apap/Caffeine
Prescriptionब्रांड नाम: BUTAL/APAP/CAFFEINE
About This Medication
Butalbital, Acetaminophen and Caffeine Tablets, USP are supplied in tablet form for oral administration. Each tablet contains the following active ingredients: butalbital, USP 50 mg acetaminophen, USP 325 mg caffeine, USP 40 mg Inactive Ingredients: silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, and stearic acid. Butalbital (5-allyl-5-isobutylbarbituric acid), is a short to intermediate-acting barbiturate. It has the following structural formula: [Chemical Structure] C11H16N2O3 M.W. 224.26 Acetaminophen (4'-hydroxyacetanilide), is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula: [Chemical Structure] C8H9NO2 M.W. 151.16 Caffeine (1,3,7-trimethylxanthine), is a central nervous system stimulant. It has the following structural formula: [Chemical Structure] C8H10N4O2 M.W. 194.19
सक्रिय तत्व
| घटक | शक्ति |
|---|---|
| Acetaminophen | - |
| Butalbital | - |
| Caffeine | - |
संकेत और उपयोग
खुराक और प्रशासन
Side Effects Overview
चेतावनियाँ और सावधानियाँ
Hepatotoxicity Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophen-containing products. The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen. Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well. Serious skin reactions Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs of serious skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity. Hypersensitivity/anaphylaxis There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs included swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergency medical attention. Instruct patients to discontinue Butalbital, Acetaminophen and Caffeine Tablets, USP immediately and seek medical care if they experience these symptoms. Do not prescribe Butalbital, Acetaminophen and Caffeine Tablets, USP for patients with acetaminophen allergy. Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.
प्रतिनिर्देश
This product is contraindicated under the following conditions: – Hypersensitivity or intolerance to any component of this product – Patients with porphyria.
Frequently Asked Questions
Butalbital, acetaminophen and caffeine tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.
One or two tablets every four hours as needed. Total daily dosage should not exceed 6 tablets. Extended and repeated use of this product is not recommended because of the potential for physical dependence.
Hepatotoxicity Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophen-containing products. The risk of acute …
This product is contraindicated under the following conditions: – Hypersensitivity or intolerance to any component of this product – Patients with porphyria.
Butal/Apap/Caffeine is a prescription medication. You will need a valid prescription from a licensed healthcare provider.
Similar Tablet Products
Browse all Tablet products →References & Data Sources
- • DailyMed — Butal/Apap/Caffeine drug label (National Library of Medicine)
- • openFDA — Butal/Apap/Caffeine label data (U.S. Food & Drug Administration)
- • RxNorm — RXCUI 238154 (NLM Normalized Drug Names)
- • NDC Directory — Butal/Apap/Caffeine (FDA National Drug Code)
चिकित्सा अस्वीकरण
इस पृष्ठ पर दी गई जानकारी केवल शैक्षणिक उद्देश्यों के लिए है और इसे पेशेवर चिकित्सा सलाह, निदान या उपचार के विकल्प के रूप में उपयोग नहीं किया जाना चाहिए।
किसी चिकित्सा स्थिति या दवा के बारे में आपके किसी भी प्रश्न के लिए हमेशा अपने चिकित्सक या अन्य योग्य स्वास्थ्य सेवा प्रदाता की सलाह लें।
डेटा स्रोत: DailyMed (NLM), openFDA, MFDS